Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multicenter phase II study conducting in 3 medical centers
in Asia. Patients will receive erlotinib in combination with bevacizumab or erlotinib alone.
This study will enroll EGFR-mutant NSCLC patients who have asymptomatic brain metastases.
The primary objective is to compare the systemic progression-free survival (PFS) to
bevacizumab plus erlotinib versus erlotinib alone in patients with EGFR mutant NSCLC who have
asymptomatic brain metastases.